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Background: Tigilanol tiglate, a short-chain diterpene ester, is being developed as intratumoral treatment of a
broad range of cancers. We conducted the first-in-human study of intratumoral tigilanol tiglate in patients
with solid tumors.
Methods: Tigilanol tiglate was administered in a multicentre, non randomized, single-arm study, with esca-
lating doses beginning with 0¢06 mg/m2 in tumors estimated to be at least twice the volume of injection
(dose-escalation cohorts). Patients with smaller tumors were assigned to the local effects cohort and received
the appropriate dose for tumor size.
Findings: Twenty-two patients were enrolled. The maximum dose was 3¢6 mg/m2 and the maximum toler-
ated dose was not reached. There was one report of dose-limiting toxicity (upper airway obstruction), two
serious adverse events (upper airway obstruction and septicemia), 160 treatment-emergent adverse events,
and no deaths. Injection site reactions in all tumors and tumor types occurred even at the lowest dose. Six of
the 22 patients experienced a treatment response, with four of the six patients achieving complete response.
Interpretation: Intratumoral tigilanol tiglate was generally well tolerated, the maximum tolerated dose was
not reached, and clinical activity was observed in 9 tumor types including complete response in four patients.
These results support the continued development of tigilanol tiglate for intratumoral administration.
Funding: QBiotics Group Limited Brisbane, Queensland, Australia was the sponsor of the study.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords:
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Surgery and radiotherapy remain the conventional approaches to
local treatment of malignant tumors, but these modalities can be lim-
ited by the location, accessibility, and size of the tumor and availabil-
ity of medical facilities. Intratumoral (IT) administration of anti-
neoplastic agents has been a treatment option for many years [1] and
represents an alternative to surgery and radiotherapy in patients
with localized accessible tumors, providing high drug concentrations
at the tumor site with minimal exposure of non-target tissues [2].
A number of agents across different drug classes are being studied in
the setting of IT administration [35].
Tigilanol tiglate (EBC-46) is a novel short-chain diterpene ester
derived from the seeds of the native Australian blushwood tree(Fontainea picrosperma) [6] and is currently in development for the
local treatment of a broad range of tumors [7-9].
Tigilanol tiglate induces a respiratory burst from human poly-
morphonuclear leukocytes [7] and when injected directly into a
tumor, increases vascular endothelial permeability, provokes
mitochondrial swelling and plasma membrane destruction in
tumor cells, inhibits the growth and induces cell death of a num-
ber of human tumor cell lines [9]. It also induces a transcriptional
profile with the characteristics of a Th1 immune response, sug-
gesting an immunomodulatory effect that may play a role in
tumor regression [10].
Tigilanol tiglate is a potent activator of protein kinase C (PKC) [9],
which comprises a family of enzymes that induce changes in signal
transduction pathways modulating diverse cellular responses includ-
ing cell replication [11-14]. Recent clinical data support a tumor sup-
pressive effect for PKC [15,16], although earlier studies suggested an
oncogenic role [17].
Research in Context
Evidence before this study
Intratumoral injection therapy for cancer currently remains a topic
of intense interest, even though current clinical research is heavily
focused on immunotherapy. As of January 2019, the PubMed data-
base lists 3671 references under the search term "intratumoral
injection”. Injection of antineoplastic agents directly into a tumor
not only reduces systemic exposure, minimizes off-target toxicity,
and limits the total amount of drug used but also induces robust
antitumor activity in the injected lesion and, potentially, in non-
contiguous non-injected lesions. Tigilanol tiglate possesses antitu-
mor activity and appears to be effective and well tolerated when
injected intralesionally as an alternative to surgery for canine mast
cell tumors and soft tissue sarcomas in veterinary settings. Studies
in syngeneic and xenograft mouse models showed that intratu-
moral injection of tigilanol tiglate into subcutaneous tumors
resulted in PKC-dependent hemorrhagic necrosis within 24 h,
complete loss of viable tumor cells, and marked vascular disrup-
tion at 24 h after treatment.
Added value of this study
Although surgery and radiotherapy constitute the great major-
ity of local therapies for tumors, their application and effective-
ness can be limited by many factors such as the overall status of
the patient, proximity and/or infiltration of tumors into adja-
cent tissues, tumor inaccessibility, large tumour volume, intol-
erance of normal tissue to repeated courses of treatment, the
presence of metastases and the availability of local facilities in
developing nations. As a consequence, better local therapies are
still needed for a wide range of tumors to reach the expanding
network of infiltrating malignant cells that can be missed by
surgery, to spare nearby normal tissue that would be damaged
by radiation, and to control tumors that are otherwise untreat-
able. This study contributes to the body of knowledge support-
ing the utility of intratumoral injection as a component of local
anticancer therapy and specifically to the role of PKC activation
in solid tumor treatment.
Implications of all the available evidence
This first-in-human, dose-escalation, clinical study of the novel
small molecule tigilanol tiglate administered intratumorally to
patients with a range of cutaneous, subcutaneous, or nodal
tumors showed that intratumoral administration of tigilanol
tiglate is generally well tolerated, a maximum tolerated dose
was not declared, and there were preliminary signs of efficacy.
These results support the continued development of tigilanol
tiglate for intratumoral administration. Future studies could
include dosing levels based on target tumor volume ranges. To
elucidate further the potential clinical usefulness of intratu-
moral therapy generally and tigilanol tiglate particularly, longer
follow-up periods (for wound healing and efficacy assessments)
and volumetric dosing assessments on treatment day (baseline)
instead of at screening for RECIST response evaluations should
be considered.
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that a single IT injection of tigilanol tiglate produced vascular disrup-
tion, hemorrhagic necrosis, an acute highly localized inflammatory
response, rapid tumor cell death and regression of solid tumors
[7,9,10,18]. In addition, numerous veterinary clinical studies have
demonstrated that tigilanol tiglate administered IT was effective
against neoplasms such as cutaneous mast cell tumors and soft tissuesarcomas [8,18,19]. Animal toxicity studies established that tigilanol
tiglate has an acceptable safety profile, producing significantly
greater local responses (erythema, edema, eschar formation) follow-
ing IT injection compared with injection into normal skin.
We report the first-in-human study of IT tigilanol tiglate in
patients with solid tumors. The results underpin the next phase in
the development of tigilanol tiglate for the intratumoral treatment of
solid tumors.
2. Patients and methods
2.1. Patient population
This was a Phase I, open-label, multicenter (four sites in Australia),
single-arm, non-randomized, dose-escalation study of IT tigilanol
tiglate in patients with accessible cutaneous, subcutaneous or nodal
tumors refractory to conventional therapy. Eligible patients were
>18 years with an ECOG performance status of 0 to 2 [20], a life
expectancy >12 weeks, and measurable disease. Patients were not
enrolled if they received any treatment within 3 weeks (or 6 weeks
for nitrosoureas or mitomycin C) of study treatment, had uncon-
trolled CNS metastases, or were at increased risk for bleeding, includ-
ing patients on anticoagulation. Pregnant or nursing females and
patients considered to be inappropriate candidates for the study also
were excluded. The study was approved by the Institutional Review
Boards and Independent Ethics Committees at each participating site,
and written consent by patients was required.
2.2. Study design
The primary objective was to establish the safety, tolerability and
maximum tolerated dose (MTD) of IT tigilanol tiglate. Secondary
objectives were to evaluate the preliminary efficacy of tigilanol
tiglate and determine its pharmacokinetics (PK). The exploratory
objective was to characterize the pharmacodynamics of tigilanol
tiglate through analysis of post-administration blood and tumor tis-
sue. Tigilanol tiglate was dissolved in 100% propylene glycol and
mixed 4:6 with 30 mM sodium acetate buffer (pH 4¢2) to provide sta-
bility and solubility and was provided in 2 mL vials containing
1¢5 mg/mL or 2 mg/mL. Vials of diluent (40% propylene glycol in
30 mM acetate buffer) were supplied to allow preparation of the
appropriate concentration.
Patients received tigilanol tiglate via direct bolus injection(s) into
no more than 3 selected superficial tumors on Day 1. The total admin-
istered volume of the solution was determined by body surface area
(BSA) using the formula Volume = (BSA x Dose Level)/Concentration
of Drug, where Volume is in mL, BSA is in m2, Dose Level is in mg/m2,
and Concentration of Drug is in mg/mL [21]. The solution was
injected into a volume of tumor estimated to be twice the volume of
the injected solution (e.g., 1 mL tigilanol tiglate into 2 cm3 of tumor).
Where tumors were larger than that required for the dose, a section
of the tumor was injected. When multiple tumors were treated, the
dose was divided in proportion to the target volume of each tumor.
The dose was administered using a minimal number of injections in a
fanning manner to spread the dose evenly throughout the tumor.
After assessments over 24 h, patients were discharged from the study
site on Day 2 and returned for follow-up on Days 3, 5, 8, 15, and 22
and, if wound healing or stabilization did not occur by Day 22, every
7 days thereafter until full healing or stabilization was achieved.
The study was divided into Stages 1 and 2 (Fig. 1:A and B). Stage 1
was conducted to establish the safety and tolerability of escalating
doses and concentrations of tigilanol tiglate in single-patient cohorts
until a severe treatment-emergent adverse event (TEAE) or dose-lim-
iting toxicity (DLT) occurred, or the Safety Review Committee (SRC)
determined the next stage should be commenced. TEAEs were
defined as AEs that commenced at or after the start of tigilanol tiglate
Fig. 1. A: Patient dosages.
EC = local effect cohort; RECIST = Response Evaluation Criteria in Solid Tumors.
*One patient at dose level 2¢40 mg/m2 was excluded from the efficacy population
because a post-baseline RECIST assessment of the target tumors was not performed.
yIn these cohorts, one patient experienced leakage of tigilanol tiglate, so an addi-
tional patient was added to the cohort.
zSix patients had insufficient tumor mass to be enrolled in the dose- escalation
stages and were enrolled in the LEC. These patients received the highest concentration
of tigilanol tiglate that had been shown to be tolerated, a total dose no higher than the
dose tested in the most recent dose-escalation cohort, and a minimum volume of
0¢1 mL per tumor. This cohort followed the same assessment schedule as the dose-
escalation cohorts.
xSix patients discontinued participation due to disease progression and one due to
unintentional lack of follow-up. The mean time to discontinuation was 25¢4 days
(range: 18 to 43 days).
B: Design Paradigm.
# A patient in this cohort experienced leakage following dosing, therefore a total of
four were enrolled to satisfy dose escalation rules
* A patient in this cohort was under-dosed, therefore a total of four were enrolled
to satisfy dose escalation rules.
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Cohort 2. Stage 2 was conducted to determine the safety and tolera-
bility of dose levels in cohorts of at least three patients using the con-
ventional 3 + 3 design (minimum of three patients per dose cohort,
with the potential to add an additional three patients to a cohort
based on the incidence of DLTs) [22]. Following Cohort 3, the protocol
was amended to revert the enrollment back to single-patient cohorts
(Stage 1) to reduce the number of patients exposed to doses that
were not likely to be therapeutically relevant. Escalation to the next
dose was then planned to continue until the MTD was reached or the
SRC or the sponsor determined that dose escalation should be termi-
nated. A maximum tigilanol tiglate concentration of 1¢5 mg/mL was
used for Stage 2, with any subsequent dose escalation achieved byincreases in tigilanol tiglate volume. The maximum dose used in this
study was 3¢60 mg/m2.
2.3. Safety and efficacy evaluations
The safety population comprised all enrolled patients who
received any dose of tigilanol tiglate, including those patients who
did not complete the study. Routine clinical and laboratory assess-
ments including hematology and biochemistry, and assessment of
other safety variables including injection site reactions, wound heal-
ing, and AEs were performed on Days 1 and 2 and at each follow-up
visit through Day 22 with the exceptions of hematology and bio-
chemistry (Days 1, 2, 8, 15 and 22) and wound healing (from Day 8
onwards). The injection site reaction assessed pain, erythema and
swelling of the skin or mucosa limited to the injection site and was
graded as 1 if  3 cm adjacent to the tumor borders, grade 2 if > 3 cm
and  6 cm, grade 3 if > 6 cm and grade 4 if it was life threatening,
chronically disabling or a hemorrhage. The efficacy population was
defined as all enrolled patients that received any dose of tigilanol
tiglate and had at least one post-baseline tumor response assessment.
To assess efficacy, target tumors were measured at baseline and on
Day 22 using both calipers and computed tomographic (CT) scans,
and RECIST 1¢123 criteria then were applied to assess anti-tumor
responses. Some patients had efficacy assessments beyond Day 22.
2.4. Pharmacokinetics
The PK population consisted of all enrolled patients who received
any dose of tigilanol tiglate and had an evaluable plasma concentra-
tion profile. Blood for PK and biomarker analysis was collected within
30 min prior to dosing and then 5, 15, and 30 min and 1 h, 2 h, 4 h,
6 h, 8 h and 24 h after dosing. Plasma samples were assayed for tigila-
nol tiglate maximum observed concentration (Cmax), time of Cmax
(Tmax), area under the plasma concentration-time curve from time
zero to the last quantifiable sampling point post-dose, area under the
plasma concentration-time curve extrapolated to infinity (AUC0-1),
elimination half-life, and systemic clearance in accordance with CPR
analytical laboratory method ALM-084. PK parameters were deter-
mined using Phoenix WinNonlin version 7¢0 (Pharsight Corporation,
USA).
2.5. Statistical analysis
The currently supported version of SAS Software (Version 9¢4)
was used to perform all data analyses.
Continuous variables were summarized using the statistical mean,
median, standard deviation, minimum and maximum. Mean with stan-
dard deviation, and median with interquartile range, were presented to
one more decimal place. Categorical variables were summarized with
frequency counts and percentages. Percentages were rounded to one
decimal place, with the relevant patient population being the denomi-
nator. Only basic descriptive statistics were performed.
The sample size for this study had been selected without perform-
ing a power calculation to provide descriptive information on safety,
tolerability, and PK following administration of tigilanol tiglate and
was done to minimize the number of patients exposed to potentially
sub-therapeutic levels of the drug.
3. Results
3.1. Patient characteristics
Of the 22 patients enrolled in the study, 15 (68%) were male and
seven (32%) were female; the median age was 64 years (range: 31 to
86 years); and 21 were Caucasian and one was Asian. At enrolment,
seven patients had AJCC stage IV disease (32%), four had stage III
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was not known and/or not recorded for four patients (18%). The first
patient was consented and screened on 13 Feb 2015 and the last
patient consented and screened on 30 May 2017. The last follow-up
assessment (Patient 206  Day 64) was on 30 Jun 2017. A total of 29
tumors representing nine tumor types were treated in the 22
patients; squamous cell carcinoma was present in ten patients, fol-
lowed by melanoma in three, basal cell carcinoma and breast adeno-
carcinoma in two each, and single cases of atypical fibroxanthoma,
atypical myxoid fibrosarcoma, metastatic colorectal adenocarcinoma,
adenoid cystic carcinoma and angiosarcoma. Seventeen patients had
single tumors treated, three had two tumors treated, and two had
three tumors treated. Thirteen patients (59%) had at least one ante-
cedent oncologic surgical procedure and 17 (77%) had received che-
motherapy or radiotherapy. Fifteen patients completed the study and
seven were deemed to have discontinued (6 after Day 22) as all of
their injection site wounds had not healed or stabilized and the
investigators felt the patients’ disease progressed to the point where
they should be taken off study.3.2. Dose escalation
Single-patient cohorts 1 and 2 of Stage 1 received 0¢06 and
0¢12 mg/m2 of tigilanol tiglate, respectively, and no DLTs were
observed (Table 1). Per protocol, transition to Stage 2 then proceeded
and four patients were dosed in Cohort 3 at 024 mg/m2; the fourth
patient was enrolled because leakage of study drug out of the tumor
following IT injection occurred in one patient. Given the satisfactory
tolerability of IT tigilanol tiglate in Cohort 3, the protocol was
amended to allow resumption of Stage 1 (single-patient cohorts), and
this was continued through three dose levels to 2¢4 mg/m2. At this
dose, a DLT of airway swelling was encountered, which led to transi-
tion to a second Stage 2 and expansion of the cohort to a total of four
patients (Cohorts 6 and 7). Escalation then proceeded to the 3¢6 mg/
m2 dose level, which was completed without DLT. Although MTD
was not reached in the study, dose escalation in the second Stage 2
was discontinued at the Cohort 8 dose level of 3¢6 mg/m2, which was
deemed by the sponsor to have provided an appropriate balance of
safety and potential efficacy.3.3. Safety and tolerability
The vast majority of AEs (96%) were mild to moderate: 135 events
were assessed as Grade 1, 81 as Grade 2, six as Grade 3 (four reports
of injection site pain and single reports of abdominal pain andTable 1
Tigilanol tiglate dose level by cohort.
Stage Cohort* Cohort dose level
(mg/m2)
Tigilanol tiglate
concentration
(mg/mL)
No. of patients
1 1 0¢06 0¢25 1
1 2 0¢12 0¢50 1
2 3 0¢24 1¢00 4y
1 4 0¢60 1¢50 1
1 5 1¢20 1¢50 1
1 6 2¢40 1¢50 1
2 7 2¢40 1¢50 3
2 8 3¢60 1¢50 4y
N/A LEC Various 1¢50 6z
N/A = not applicable.
* If no dose-limiting toxicity occurred, the subsequent cohort received the next
highest dose.
y One patient experienced leakage of tigilanol tiglate, so an additional patient
was included in the cohort.
z LEC (local effect cohort) included nominal doses of 0¢6mg/m2 (n = 1), 1¢2mg/m2
(n = 4), and 2¢4 mg/m2 (n = 1).stridor), and two as Grade 4 (life-threatening upper airway obstruc-
tion and sepsis, respectively). There was one DLT and there were two
serious AEs, 160 TEAEs, and no deaths. The DLT (upper airway
obstruction) occurred in a patient who was treated with 2¢4 mg/m2.
The two serious AEs were sepsis and upper airway obstruction (also
the above DLT). Sepsis due to Streptococcus pyogenes, which was con-
sidered possibly related to IT tigilanol tiglate, developed 6 weeks
after IT injection and subsequent tumor ulceration in an elderly male
with chronic venous insufficiency and an atypical fibroxanthoma on
his leg, which eventually healed without evidence of residual tumor.
Upper airway obstruction, which developed after subcutaneous
infra-auricular/upper neck IT injection, was considered probably
related to IT tigilanol tiglate because of altered anatomy including
lymphatic drainage after surgery (neck dissection) and radiotherapy
(undertaken prior to recruitment to this study) and subsequent para-
pharyngeal edema necessitating a precautionary tracheostomy.
Abdominal pain was considered “not related” to IT tigilanol tiglate.
The most common AE was injection site reaction in 12 patients, rep-
resenting 46% of all treatment-related AEs and 33% of all TEAEs. The
observed injection site reactions were Grade 1 for eight patients,
Grade 2 for ten patients, and Grade 3 for four patients, and there was
an observed dose-response relationship with respect to the fre-
quency and intensity of injection site reactions. Injection site reac-
tions are shown in Fig. 2. TEAEs by nominal dose and toxicity grade
are listed in Table 2.Fig. 2. Number of patients with injection site reactions by dose cohort and grade of reac-
tion (A). Number of tumors with injection site reactions by dose cohort and grade of reac-
tion (B). LEC = Local effect cohort
Table 2
Number of TEAEs* by nominal dose level, toxicity grade and CTCAE.
Nominal dose level 0¢06 mg/m2 0¢12 mg/m2 0¢24 mg/m2 0¢6 mg/m2 1¢2 mg/m2 2¢4 mg/m2 3¢6 mg/m2
No. of patients 1 1 4 2 5 5 4
Toxicity grade 2 3 4 2 3 4 2 3 4 2 3 4 2 3 4 2 3 4 2 3 4
TEAE
Abdominal discomfort                   1  
Agitation                1     
Anxiety                1     
Cellulitis                   2  
Chills                1     
Cold sweat                   1  
Conjunctivitis             1        
" C-reactive protein                1     
Dyspnea                2   1  
Erythema             1   1   1  
Eye irritation             2        
Eye pain             1        
Eye swelling             1        
Feeling hot                   2  
Headache             2   1   1  
Hot flush                1     
Hypercalcemia 1                    
Hyperglycemia 1                    
Hypertension                1     
Hyperventilation                1     
Injection site edema                1     
Injection site pain              2  5    1 
Injection site reaction                3     
Injection site swelling                1     
" Lacrimation             1        
Nasal discomfort             1        
Neck pain                1     
Neoplasm progression                1     
Obstructive airway disorderx                  1   
Edema peripheral                1     
# Oxygen saturation                   1  
Pain             3   2     
Pyrexia                1     
" Respiratory rate                   1  
Sepsis                  1   
Skin abrasion             1        
Skin exfoliation                1     
Skin ulcer                2   1  
Stridorx                 1    
Swelling face             1        
Tachycardia                1     
Tremor                   2  
Tumor ulceration                1     
Vascular disorders                   2  
Wound secretion             1   1     
CTCAE = Common Terminology Criteria for Adverse Events [24]
* There were 53 events in 12 of the 22 patients (54¢5%) considered possibly related to tigilanol tiglate and 107 events in 12 of the 22 patients (54¢5%) considered probably
related to tigilanol tiglate (160 events in total).
x Obstructive airway disorder and stridor represent the same event in one patient.
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No clear dose-response relationship with respect to efficacy was
observed with increasing dose in the dose-escalation cohorts. Best
target tumor responses by RECIST 1¢1 criteria using caliper measure-
ments from Day 1 are shown in Table 3. Six out of 22 patients had a
treated tumor whose injected area responded according to RECIST
1¢1. One of 16 patients in the dose-escalation cohort treated with
2¢4 mg/m2 experienced a complete response (disappearance of the
injected target lesion), clinically confirmed after eventual healing of
the injection site ulceration (patient 406); three of the 16 patients
experienced partial response, one of whom was treated with 0¢6 mg/
m2, one with 0¢24 mg/m2, and one with 2¢4 mg/m2. Ten patients
experienced stable disease, one experienced progressive disease, and
response was not evaluable in one patient. Review of efficacy data
from patients in the local effect cohort (LEC) who received an appro-
priate dose for tumor size (based on animal data) revealed three ofsix patients (50%) achieving complete response, three of six (50%)
with stable disease, and none with progressive disease
Two patients in the LEC experienced anenestic tumor responses.
One of these patients (Patient 404), who had metastatic melanoma in
axillary nodal disease, fine needle aspiration-proven contralateral
parotid nodal deposit, and a clinically suspicious leg deposit,
remained clinically and ultrasonographically clear for 33 months
post-treatment but subsequently developed widespread metastatic
disease although axillary and parotid nodes remained clear. The other
patient (Patient 102) had melanoma with dermal, nodal and pleural
metastases. This patient had an earlier local response to radiation
therapy for chest wall metastases but developed progressive disease
despite receiving four doses of pembrolizumab. Patient 102 experi-
enced a complete response in the three injected cutaneous mela-
noma metastases on the right upper extremity. Significantly, a fourth
cutaneous tumor, which was not injected with study drug (seen infe-
rior to the injected lesions), experienced an anenestic response and
Table 3
Efficacy treatment response.
Cohort Patient No. Tumor (location) Nominal/ actual dose
(mg/m2)
Estimated tumor
volume (cm2)
Estimated percentage
tumor treated
Best RECIST (area of tumor
injected) response by
calipers from Day 1
Dose-escalation cohorts
1 401 SCC (back) 0¢06/0¢06 501¢0 1% SD
2 201 SCC (shin) 0¢12/0¢12 0¢9 87% SD
3 101 BCC (nose) 0¢24/0¢22 2¢1 37% SD
3 202 SCC (lateral to eyes,
behind ear)
0¢24/0¢18 0¢2 100% PR
0¢3 100%
0¢5 100%
3 301 Breast AC (chest) 0¢24/0¢24 2.4 47% PD
3 402 SCC (zygoma) 0¢24/0¢15 7¢2 10% SD
4 403 SCC (medial canthus) 0¢6/0¢59 1¢4 100% PR
5 203 SCC (inner cheek/palate) 1¢2/1¢19 12¢0 21% SD
6 405 SCC (infra-auricular) 2¢4/2¢32 58¢2 10% Not assessable
7 406 Atypical fibroxanthoma (leg) 2¢4/2¢38 13¢3 48% CR
7 408 SCC (scalp) 2¢4/2¢39 29¢5 21% SD
7 409 SCC (back) 2¢4/2¢4 27¢5 21% PR
8 103 Metastatic melanoma (leg) 3¢6/1¢76 16¢1 35% SD
8 206 Metastatic colorectal AC
(abdomen)
3¢6/3¢6 39¢0 25% SD*
8 303 Myxoid fibrosarcoma (cheek) 3¢6/3¢61 4¢7 100% SD
10¢4 60%
8 410 SCC (temporal) 3¢6/3¢47 31¢9 26% SD
Local effect cohort
LEC 404 Melanoma (axilla) 0¢6/0¢47 0¢5 100% CR followed by PDy
0¢5 89%
LEC 102 Metastatic melanoma (arm) 1¢2/0¢42 0¢7 100% CRy
0¢4 76%
0¢2 100%
LEC 407 Angiosarcoma (nose) 1¢2/0¢61 2¢1 100% CR
LEC 204 ACC (hard palate) 1¢2/1¢2 4¢4 77% SD
LEC 302 Breast AC (breast) 1¢2/0¢23 0¢2 100% SD
0¢3 100%
LEC 205 BCC (nose) 2¢4/0¢84 3¢1 100% SD
SCC = squamous cell carcinoma; AC = adenocarcinoma; ACC = adenoid cystic carcinoma; BCC = basal cell carcinoma; CR = complete response; PD = progressive disease;
PR = partial response; SD = stable disease.
* Patient 206 had no caliper measurements for RECIST so CT scan assessment is provided.
y Anenestic responses: 1) Distant effect for patient 404 on fine needle aspiration-proven contralateral parotid nodal deposit and clinically suspicious leg melanoma. Patient
clinically and ultrasound clear at 33 months post-treatment followed by systemic metastases although axillary and parotid nodes remained clear. 2) Local effect for patient
102 on most distal untreated arm lesion. See Fig. 3.
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mately 4 weeks after injection of the upper extremity lesions, a
superficial sternal lesion (biopsy-proven metastatic melanoma) was
injected, which also showed a complete response. Of note, CT scans
showed anenestic responses in non-injected lymph node and pleural
lesions, with complete resolution of an involved 24-mm left axillary
node and a 29-mm right pleural nodule, and a reduction in size of an
involved right inguinal node. The patient remained well and off treat-
ment until a CT scan performed 14 months after the second tigilanol
tiglate injection revealed progressive tumor involving bone and
lymph nodes. Patient 407, who had biopsy-proven angiosarcoma of
the nasal bridge, had been recommended for total rhinectomy. He
achieved a complete response from a single injection of tigilanol
tiglate. Three punch biopsies at 12 weeks revealed no residual tumor,
and the patient remains disease free on CT scan at 25 months and
clinically at 30¢5 months post-injection. Fig. 3 shows the changes in
tumor appearance with treatment for these four patients.
The median volume of tumors treated in the dose-escalation
cohorts was 37% of the total target tumor volume (range: 1% to 100%;
average: 50%) compared with a median of 100% (range: 76% to 100%;
average: 94%) in the LEC. The average size of tumors in the dose-esca-
lation cohorts was very large (~40 cm3, maximum ~500 cm3) com-
pared with tumors in the LEC (~1¢2 cm3, maximum ~4¢4 cm3).
Leakage from ulcerating tumors occurred following ten injections,
with a mean estimated loss of 10% to 20% of the administered vol-
ume. Median wound healing time of the treatment site was approxi-
mately 30 days post-injection.3.5. Pharmacokinetics
Individual PK profiles for dose-escalation cohorts and the LEC are
shown in Fig. 4. Review of these plots indicates that, within a few
minutes of injection, tigilanol tiglate was detected in the plasma
(median Tmax = 5 min; range: 0¢07 to 2¢0 h). Plasma concentration
then declined rapidly to low levels within 2 to 4 h post-injection, sug-
gesting that larger tumors could be treated with staged injections.
There was no apparent trend for increased half-life with increased
dose, with an overall median of 3¢64 h (range: 1¢55 to 9¢42 h). Review
of data across the cohorts demonstrated a dose-proportional increase
in systemic exposure of tigilanol tiglate, as measured by Cmax, AUC0-t,
and AUC0-1 on Day 1 for doses of 0¢06 to 3¢6 mg/m2. These PK param-
eters exhibited an approximately linear relationship with dose across
the dosing range using a power model approach.
4. Discussion
This was the first-in-human study to assess the safety and tolera-
bility, efficacy and PK of tigilanol tiglate administered via IT injection
to subcutaneous or nodal metastatic lesions in patients with
advanced primary or metastatic tumors, using a dose-escalation
design. As a first-in-human study, dose levels for the escalation
cohorts were necessarily determined by BSA rather than by target
tumor volume. As tigilanol tiglate is an IT treatment and efficacious
dosing is based on tumor volume and not BSA, efficacy results and
factors such as dosing trend have the potential to be confounded.
Fig. 3. Patient 102 Tumor response: Four melanomas of the right arm. The estimated tumor volume treated was 100% for tumors 1 and 3 and 76% for tumor 2; tumor 4 was not
treated. All target tumors had length, width, depth and volume of zero at Days 22, 29 and 36. The figure shows the progression from immediately pre-injection and 5, 8, and
22 days post-injection.
Patient 404 Tumor response: Melanoma of the axilla. The figure shows the progression from immediately pre-injection and 2, 8, and 29 days post-injection. The patient was
assessed as a complete response through 33 months with an anenestic response, followed by systemic metastases.
Patient 406 Tumor response: An atypical fibroxanthoma of the leg and experienced stable disease. The figure shows the progression from immediately pre-injection, at 2, and
22 days post-injection, and at final assessment at 7 months.
Patient 407 Tumor response: An angiosarcoma of the nose with a recommendation for total rhinectomy. The figure shows the progression from immediately pre-injection and
2, 15, and 43 days post-injection. The patient was assessed as a complete response and remains clinically disease free 30.5 months post-injection.
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in Stage 2 ceased at the Cohort 8 dose level of 3¢60 mg/m2, which
was deemed to have provided an appropriate balance between safety
and potential efficacy. Most TEAEs were related to the local effects
and mechanism of action of tigilanol tiglate. TEAEs generally were
managed with symptomatic therapy such as analgesics. Some sys-
temic exposure to tigilanol tiglate occurred and, within the range ofdoses used, the AEs related to systemic exposure appeared to be mild
to moderate, self-limited and of short duration. Future studies will
consider multiple administration of lower doses.
This study used the RECIST 1¢1 guidelines [23] for tumor assess-
ment (by calipers and CT scan), which require tumors to be at least
10 mm in one dimension, limiting the ability to include smaller
tumors. The LEC allowed patients with insufficient tumor volumes to
Fig. 4. Plasma concentration of tigilanol tiglate by dose level shown as individual PK profiles for dose-escalation cohorts (A) and LEC (B).
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that had been tolerated in a dose-escalation cohort. The median vol-
ume of target tumors treated in the dose-escalation cohort was 37%
(range: 1% to 100%, average 50%) of the BSA. In contrast, the median
volume of target tumors treated in the LEC was 100% (range: 76% to
100%, average 94%) of the BSA. In addition, the range of tumor volumes
in the dose-escalation cohort was very large (up to ~500 cm3), whereas
the LEC had a much smaller range (up to 4¢5 cm3). These factors help
explain the better responses in the LEC, which may reflect more accu-
rately the tumor responses anticipated when tigilanol tiglate is dosed
according to tumor volume in later phase trials. Three patients in the
LEC, one with three treated metastatic melanomas on the arm, onewith axillary node recurrence in a previously dissected area, and one
with angiosarcoma on the nose, experienced complete response; two
experienced complete response within the study period and one even-
tually outside this period. Both melanomas demonstrated an anenestic
effect. Possible mechanisms for the regression of a tumor outside the
scope of localized treatment could include exposure to tigilanol tiglate
by lymphatic drainage, bystander inflammatory response, or systemic
activation of the immune system. The responses in the LEC are espe-
cially encouraging, as signals of clinical efficacy were identified despite
the many inter- and intra-patient variables including; a variety of
tumors and tumor volumes, different anatomic sites and a predomi-
nantly late stage setting.
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ing might be explained by the known high vascularity of tumors. How-
ever, the study did not measure IT concentrations, although animal
data have demonstrated that tigilanol tiglate levels achieved within
the tumor were significantly higher than those reached in plasma [7].
5. Conclusion
In this first-in-human Phase I study, IT administration of tigilanol
tiglate was generally well tolerated, the MTD was not reached, and
signals of clinical efficacy were identified across nine tumor types.
Four patients- two with metastatic melanoma, one with atypical
fibroxanthoma and one with angiosarcoma -achieved complete
response in the treated lesions, with the two melanoma patients
demonstrating an anenestic response. These results support the con-
tinued development of tigilanol tiglate for IT administration into a
Phase II efficacy trial and provide evidence of the potential role of
PKC activation in the treatment of solid tumors.
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